Results 211 to 220 of about 7,721,321 (318)

Host-response biomarker MxA for etiological discrimination of pediatric lower respiratory tract infections: implications for diagnostic study design. [PDF]

Transl Pediatr
Guo Y, Li P.
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

A School-Based Nutrition and Physical Activity Intervention for the Prevention of Childhood Obesity: Study Design and Baseline Findings From a Cluster-Randomized Trial. [PDF]

J Nutr Metab
Nóvoa-Medina Y, Leon SDC, Barreiro-Bautista M, Batista-Dávila V, Fabelo H, Pavlovic S, García-Delgado Y, Jiménez JE, López-López S, Gran Canarian Diabetes and Obesity Research Group, Wägner AM, Peña-Quintana L.   +11 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Machine learning-based unified models for predicting drug clearance from pharmacokinetic animal and study design variables. [PDF]

PLoS One
Ampadi Ramachandran R, Tell LA, Mercer MA, Xu X, Millagaha Gedara NI, Clapham MO, Lin Z, Riviere JE, Jaberi-Douraki M.   +8 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Spatial omics in high-grade glioma: study design, analytical pitfalls, and standards for reproducible neuro-oncology. [PDF]

Acta Neuropathol Commun
Abdullah IA, Arora I, Shaikh S, Raziq T, Alfares SB, Raslan TT, Siddiqui MS, Saleh SH, Akbar A, Khan MI, Yaqinuddin A.   +10 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Introduction to case-crossover study design for drug-drug interaction. [PDF]

Ann Clin Epidemiol
Yu Q, Wong AY.
europepmc   +1 more source